This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Deracoxib
DrugBank Accession Number
DB11395
Background

Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with orthopedic surgery in dogs.

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 397.37
Monoisotopic: 397.070796986
Chemical Formula
C17H14F3N3O3S
Synonyms
  • Déracoxib
  • Deracoxib
  • Deracoxibum
External IDs
  • SC 046
  • SC 59046
  • SC-59046

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Deramaxx

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Pyrazoles
Direct Parent
Phenylpyrazoles
Alternative Parents
Benzenesulfonamides / Benzenesulfonyl compounds / Phenoxy compounds / Anisoles / Methoxybenzenes / Alkyl aryl ethers / Fluorobenzenes / Organosulfonamides / Aryl fluorides / Aminosulfonyl compounds
show 8 more
Substituents
Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Aminosulfonyl compound / Anisole / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenesulfonamide
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrazoles, sulfonamide (CHEBI:73032)
Affected organisms
Not Available

Chemical Identifiers

UNII
VX29JB5XWV
CAS number
169590-41-4
InChI Key
WAZQAZKAZLXFMK-UHFFFAOYSA-N
InChI
InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)
IUPAC Name
4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
SMILES
COC1=C(F)C=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)F

References

General References
  1. Wiwanitkit V: Use of deracoxib during intense rehabilitation exercises. Vet Comp Orthop Traumatol. 2010;23(6):472. [Article]
  2. Gassel AD, Tobias KM, Cox SK: Disposition of deracoxib in cats after oral administration. J Am Anim Hosp Assoc. 2006 May-Jun;42(3):212-7. [Article]
  3. Case JB, Fick JL, Rooney MB: Proximal duodenal perforation in three dogs following deracoxib administration. J Am Anim Hosp Assoc. 2010 Jul-Aug;46(4):255-8. [Article]
  4. Karnik PS, Johnston S, Ward D, Broadstone R, Inzana K: The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model. Vet Surg. 2006 Jan;35(1):34-42. [Article]
  5. Kahn SA, Mullin CM, de Lorimier LP, Burgess KE, Risbon RE, Fred RM 3rd, Drobatz K, Clifford CA: Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. Can Vet J. 2013 Mar;54(3):237-42. [Article]
  6. Davis JL, Marshall JF, Papich MG, Blikslager AT, Campbell NB: The pharmacokinetics and in vitro cyclooxygenase selectivity of deracoxib in horses. J Vet Pharmacol Ther. 2011 Feb;34(1):12-6. doi: 10.1111/j.1365-2885.2010.01185.x. [Article]
  7. Tomlinson JE, Blikslager AT: Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum. Equine Vet J. 2005 Jan;37(1):75-80. [Article]
  8. Sennello KA, Leib MS: Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs. J Vet Intern Med. 2006 Nov-Dec;20(6):1291-6. [Article]
  9. Ustun Alkan F, Ustuner O, Bakirel T, Cinar S, Erten G, Deniz G: The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal. 2012;2012:976740. doi: 10.1100/2012/976740. Epub 2012 Nov 7. [Article]
KEGG Drug
D03689
ChemSpider
2319853
BindingDB
50057583
RxNav
356834
ChEBI
73032
ChEMBL
CHEMBL28636
ZINC
ZINC000000607803
Wikipedia
Deracoxib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0104 mg/mLALOGPS
logP3.39ALOGPS
logP2.76ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)10.7ChemAxon
pKa (Strongest Basic)0.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.21 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93 m3·mol-1ChemAxon
Polarizability35.83 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at February 25, 2016 18:23 / Updated at February 21, 2021 18:53